CytomX Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . CytomX Therapeutics
CTMX Stock  USD 4.26  0.10  2.40%   
CytomX Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing CytomX Therapeutics' valuation are provided below:
Gross Profit
113.6 M
Profit Margin
0.2466
Market Capitalization
721.8 M
Enterprise Value Revenue
5.1374
Revenue
113.6 M
We have found one hundred twenty available fundamental signals for CytomX Therapeutics, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of CytomX Therapeutics prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 95 M in 2026. Enterprise Value is likely to drop to about 63.7 M in 2026

CytomX Therapeutics Total Revenue

166.76 Million

Check CytomX Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CytomX Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2 M, Interest Expense of 2.1 M or Selling General Administrative of 29.1 M, as well as many indicators such as Price To Sales Ratio of 0.69, Dividend Yield of 0.0072 or Days Sales Outstanding of 8.96. CytomX financial statements analysis is a perfect complement when working with CytomX Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with CytomX Stock
Check out the analysis of CytomX Therapeutics Correlation against competitors.
For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.

CytomX Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets271.4 M138.6 M200.8 M
Slightly volatile
Short and Long Term Debt Total16.4 M10.8 M15.9 M
Slightly volatile
Other Current Liabilities17.6 M14.2 M13.3 M
Slightly volatile
Total Current Liabilities80.7 M98.6 M63.1 M
Slightly volatile
Other Liabilities151.2 M207.1 M124.2 M
Slightly volatile
Property Plant And Equipment Net14.6 M12.2 M11.3 M
Slightly volatile
Current Deferred Revenue55.9 M77.3 M43.9 M
Slightly volatile
Accounts Payable930.2 K979.2 K2.6 M
Very volatile
Cash41.6 M43.8 M94.6 M
Slightly volatile
Non Current Assets Total19.1 M15.2 M15.1 M
Slightly volatile
Other Assets1 M1.1 M2.7 M
Pretty Stable
Cash And Short Term Investments109.9 M115.7 M170 M
Slightly volatile
Net Receivables5.5 M3.6 M4.1 M
Slightly volatile
Good Will759.2 K854.1 K932.3 K
Slightly volatile
Common Stock Total Equity800900982
Slightly volatile
Common Stock Shares Outstanding51.9 M97.5 M42.3 M
Slightly volatile
Short Term Investments113.7 M72 M83.9 M
Slightly volatile
Liabilities And Stockholders Equity271.4 M138.6 M200.8 M
Slightly volatile
Non Current Liabilities Total38.5 M40.5 M120.1 M
Very volatile
Inventory0.860.929.4 K
Slightly volatile
Other Current Assets6.5 M4.1 M4.9 M
Slightly volatile
Total Liabilities245.6 M139.1 M190.6 M
Slightly volatile
Property Plant And Equipment Gross17.4 M30.9 M14.4 M
Slightly volatile
Total Current Assets117.2 M123.4 M177.7 M
Slightly volatile
Short Term Debt4.8 M5.9 M5.5 M
Pretty Stable
Intangible Assets498.5 K524.7 K1.3 M
Slightly volatile
Common Stock800900982
Slightly volatile
Property Plant Equipment8.3 M6.9 M6.4 M
Slightly volatile
Deferred Long Term Liabilities319.6 M304.4 M187.5 M
Slightly volatile
Short and Long Term Debt1.1 M1.3 M1.4 M
Slightly volatile
Capital Surpluse474.2 M716.8 M417.9 M
Slightly volatile
Non Current Liabilities Other4.5 M4.7 M37.7 M
Slightly volatile
Net Working Capital18.4 M19.4 M222.5 M
Slightly volatile
Capital Stock800900982
Slightly volatile
Capital Lease Obligations15.4 M8.4 M22.9 M
Slightly volatile

CytomX Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization2 M2 M1.7 M
Slightly volatile
Selling General Administrative29.1 M34.2 M23.3 M
Slightly volatile
Total Revenue166.8 M158.8 M57.4 M
Slightly volatile
Gross Profit166.8 M158.8 M57.4 M
Slightly volatile
Other Operating Expenses116.2 M130.1 M91.8 M
Slightly volatile
Research Development87.1 M95.9 M68.6 M
Slightly volatile
Total Operating Expenses116.2 M130.1 M91.8 M
Slightly volatile
Interest Income4.5 M8.2 M3.2 M
Slightly volatile
Net Interest Income4.7 M8.2 M3.3 M
Slightly volatile
Non Operating Income Net Other147.1 K154.8 K2.2 M
Slightly volatile
Reconciled Depreciation2.5 M2 M2 M
Slightly volatile
Extraordinary Items20.6 M23.1 M25.2 M
Slightly volatile
Selling And Marketing Expenses116.8 K131.4 K143.4 K
Slightly volatile

CytomX Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation11 M8.8 M8.3 M
Slightly volatile
Begin Period Cash Flow19.8 M20.8 M92 M
Slightly volatile
Other Cashflows From Financing Activities524.1 K551.7 K9.6 M
Very volatile
Depreciation2.3 M2 M1.9 M
Slightly volatile
Capital Expenditures265.1 K279 K1.4 M
Very volatile
Total Cash From Financing Activities6.4 M6.8 M31.4 M
Very volatile
End Period Cash Flow42.7 M44.9 M95 M
Slightly volatile
Sale Purchase Of Stock133.1 M126.7 M52.4 M
Slightly volatile
Change To Netincome14.7 M15.1 M10.5 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.690.7218.4562
Slightly volatile
Dividend Yield0.00720.00810.0089
Slightly volatile
Days Sales Outstanding8.969.4356.8332
Slightly volatile
Stock Based Compensation To Revenue0.06070.06390.2633
Slightly volatile
Capex To Depreciation0.190.20.9537
Slightly volatile
Sales General And Administrative To Revenue0.240.251.8528
Slightly volatile
Research And Ddevelopement To Revenue0.660.694.5177
Slightly volatile
Capex To Revenue0.00250.00260.2499
Slightly volatile
Cash Per Share1.31.375.5994
Slightly volatile
Intangibles To Total Assets0.02860.01460.0545
Slightly volatile
Current Ratio1.371.443.657
Slightly volatile
Receivables Turnover38.0540.06316
Very volatile
Capex Per Share0.0040.00420.2029
Slightly volatile
Revenue Per Share0.811.471.0091
Slightly volatile
Interest Debt Per Share0.120.131.2802
Slightly volatile
Debt To Assets0.110.08950.1283
Slightly volatile
Operating Cycle8.969.4356.8332
Slightly volatile
Quick Ratio1.371.443.6508
Slightly volatile
Cash Ratio0.480.512.1613
Slightly volatile
Cash Conversion Cycle8.969.4356.8332
Slightly volatile
Days Of Sales Outstanding8.969.4356.8332
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.181.151.0851
Pretty Stable
Fixed Asset Turnover12.3111.725.0584
Slightly volatile
Debt Ratio0.110.08950.1283
Slightly volatile
Price Sales Ratio0.690.7218.4562
Slightly volatile
Asset Turnover1.081.030.3044
Slightly volatile

CytomX Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap95 M100 M265.4 M
Very volatile

CytomX Fundamental Market Drivers

Forward Price Earnings14.2045
Cash And Short Term Investments100.6 M

CytomX Upcoming Events

25th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
25th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About CytomX Therapeutics Financial Statements

CytomX Therapeutics investors use historical fundamental indicators, such as CytomX Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in CytomX Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue77.3 M55.9 M
Total Revenue158.8 M166.8 M
Cost Of Revenue1.6 M1.5 M
Stock Based Compensation To Revenue 0.06  0.06 
Sales General And Administrative To Revenue 0.25  0.24 
Research And Ddevelopement To Revenue 0.69  0.66 
Revenue Per Share 1.47  0.81 
Ebit Per Revenue 0.16  0.17 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
JBLJabil Circuit
MRKMerck Company
AMGNAmgen Inc

Additional Tools for CytomX Stock Analysis

When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY